Characteristic | N (%) |
---|---|
Patient Sex | |
Male | 34 (64.2) |
Female | 19 (35.9) |
Patient age at diagnostic (years) | |
Median (interquartile range) | 61 (20–84) |
Patient age at Radiofrequency ablation treatment (RFA) (years) | |
Median (interquartile range) | 67 (29–86) |
Treatment before RFA (per patient) | 28 (53) |
Interferon | 18 (34) |
Sunitinib | 9 (17) |
Sorafenib | 1 (2) |
Primary histology (per patient) | |
Clear cell carcinoma | 48 (90) |
Papillary carcinoma | 1 (2) |
Mucinous tubular renal cell carcinoma RCC missing information | 1 (2)1 (2) |
Sarcomatoid component (10%) | 2 (4) |
T staging (per patient) | |
T1 – T2 | 19 (36) |
T3 – T4 | 25 (47) |
Unknown | 9 (17) |
Tumor size in mm (per lesion) | |
< 10 | 32 (32) |
10 < x < 20 | 43 (43) |
20 < x < 30 | 15 (15) |
≥ 30 | 9 (9) |
missing | 1 (1) |
Time to metastasis (months) | |
Median (interquartile range) | 22 (7–53) |
Number of metastases (per patient) | |
1 | 25 (47) |
2 | 11 (21) |
3 | 9 (17) |
4–6 | 8 (15) |
Number of RFA treatments (per patient) | |
1 | 41 (77) |
2 | 12 (23) |
Fuhrman grade (per patient) | |
1 | 1 (2) |
2 | 9 (17) |
3 | 26 (49) |
4 | 5 (9) |
Unknown | 2 (3) |
Time to recurrence (all types, per patient) | |
≤ 12 months | 20 (38) |
> 12 months | 33 (62) |
Concomitant metastases (per patient) | |
Concomitant | 10 (19) |
Delayed | 43 (81) |